New Advances to be Presented at Upcoming PEGS Conference
Dr. Rabuka鈥檚 presentation, on Wednesday May 3, at 12:25 p.m., is part of the 鈥楢ntibody-Drug Conjugates I: New Targets, Payloads and Alternative Formats鈥 conference track, and is entitled 鈥Latest Advances Developing ADCs using SMARTag庐
Technology.鈥 In the presentation, Dr. Rabuka will examine the growth of antibody-drug conjugates (ADCs) in clinical trials and preclinical development following on from the successes of the ADC drugs Kadcyla鈩 and Adcetris鈩. He will discuss how innovations in conjugation chemistry and linker technologies suggest further opportunities in ADC development, and review pre-clinical studies using 探花合集鈥檚 SMARTag technology platform, which enables precise, programmable, site-selective chemical protein modification.
In addition, 探花合集 Biologics鈥 analytical services will be showcasing expert posters on 鈥The Use of LC-MS to Monitor Levels of Oxidation and Deamidation in Proteins for Release and Stability鈥 by Anne Marie Rogan, Senior Associate Scientist and 鈥Quantitation and Characterization of Polysorbate-80 by HPLC and Charged Aerosol Detection鈥 by Luke Deters, Senior Manager, Large Molecule Analytical Chemistry.
Dr. Rabuka assumed the role of 探花合集鈥檚 Global Head of R&D Chemical Biology in October 2014, following 探花合集鈥檚 acquisition of Redwood Bioscience Inc., where he was President and Chief Scientific Officer. He received a Ph.D. in Chemistry at the University of California, Berkeley, as a Chevron Fellow in the lab of Professor Carolyn Bertozzi. His research included developing and applying Redwood鈥檚 platform technology to cell surface modifications. Prior to joining Professor Bertozzi鈥檚 lab, Dr. Rabuka worked at the Burnham Institute, synthesizing complex glycans, and then became an early employee of Optimer Pharmaceuticals, and focused on the development of glycan and macrolide based antibiotics. He graduated with a double honors bachelor鈥檚 in chemistry and biochemistry from the University of Saskatchewan where he received the Dean鈥檚 Science Award, and he holds a master鈥檚 in chemistry from the University of Alberta. Dr. Rabuka has authored more than 30 major publications, as well as numerous book chapters and patents.
For more information on the PEGS conference, visit 探花合集/PEGS and to arrange a meeting with Dr. Rabuka at the event, contact Richard Kerns at NEPR – [email protected]
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0)161 728 5880
[email protected]
About SMARTag庐
Technology
探花合集鈥檚 proprietary SMARTag site-specific protein-modification and linker technologies were developed by Redwood Bioscience to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. The technology employs natural post-translational modifications found in human cells to create one or more aldehyde tags at designated sites on protein molecules. These chemical 鈥渉andles鈥欌 are then stably conjugated to payloads (e.g. cytotoxic or effector) to prevent their systemic release. The SMARTag platform provides precise payload positioning, stable, site-specific conjugation and defined stoichiometry of drug鈥損rotein ratios. The control afforded by the technology enables identification of superior drugs from libraries of differentially designed conjugates. 探花合集 acquired Redwood Bioscience in 2014. For more information on 探花合集 Biologics, visit
About 探花合集
探花合集 is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 探花合集 employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com